|
|
| Orchid Chemicals & Pharmaceuticals Ltd. |
| UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011 |
| |
(Rs.Lakhs) |
| S.NO |
Particular |
Unaudited |
Audited |
Three months
ended
30-Jun-11 |
Three months
ended
30-Jun-10 |
Year
ended
31-Mar-11 |
| 1 |
Net Sales / Income from Operations |
37,376.02 |
30,350.00 |
159,467.88 |
| 2 |
Other operating Income |
982.87 |
2,742.83 |
7,359.63 |
| 3 |
Total Operating Income (1+2) |
38,358.89 |
33,092.83 |
166,827.51 |
| 4 |
Expenditure |
|
|
|
| |
a) Decrease/ (Increase) in Stock in trade |
(4,846.40) |
(2,192.44) |
(11,964.59) |
| |
b) Material cost |
21,978.82 |
16,224.53 |
86,798.76 |
| |
c) Purchase of Traded Goods |
1,435.55 |
961.36 |
3,961.66 |
| |
d) Employees Cost |
3,866.78 |
3,032.85 |
14,138.46 |
| |
e) Depreciation / Amortisation |
3,530.47 |
3,226.03 |
12,845.43 |
| |
f) Other Expenditure |
7,226.60 |
6,688.73 |
32,552.72 |
| |
g) Total |
33,191.82 |
27,941.06 |
138,332.44 |
| 5 |
Profit from Operations before Other Income, Interest & Exceptional Item (3-4) |
5,167.07 |
5,151.77 |
28,495.07 |
| 6 |
Other Income |
- |
- |
267.10 |
| 7 |
Profit / (Loss) before Interest & Exceptional Item (5+6) |
5,167.07 |
5,151.77 |
28,762.17 |
| 8 |
Interest & Finance Charges |
3,074.74 |
2,271.27 |
11,576.50 |
| 9 |
Profit/(loss) after interest but before Exceptional Item (7-8) |
2,092.33 |
2,880.50 |
17,185.67 |
| 10 |
Exceptional Item - Gain/(Loss) |
(107.26) |
(469.86) |
194.82 |
| 11 |
Profit/(Loss) before Tax (9+10) |
1,985.07 |
2,410.64 |
17,380.49 |
| 12 |
Tax expenses |
|
|
|
| |
- Current Tax & Deferred Tax |
430.82 |
249.16 |
1,432.13 |
| 13 |
Net Profit/(Loss) after Tax (11-12) |
1,554.25 |
2,161.48 |
15,948.36 |
| 14 |
Paid-up Equity Share Capital |
7,044.21 |
7,044.21 |
7,044.21 |
| |
(Face value of Rs.10/- each) |
|
|
|
| 15 |
Reserves excluding Revaluation Reserves |
- |
- |
106,358.27 |
| 16 |
Earnings per share (EPS)
- Basic Rs. |
2.21* |
3.07* |
22.64 |
| |
- Diluted Rs. |
1.82* |
2.44* |
18.71 |
| 17 |
Aggregate of Public Shareholding |
|
|
|
| |
- Number of equity shares |
48939460 |
52128460.00 |
48939460 |
| |
- Percentage of Shareholding |
69.47 |
74.00 |
69.47 |
| 18 |
Promoters and Promoter group shareholding |
|
|
|
| |
a. Pledged / Encumbered |
|
|
|
| |
- Number of shares |
15745383 |
14824327 |
17181383 |
| |
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) |
73.23 |
80.95 |
79.90 |
| |
- Percentage of shares (as a % of the total share capital of the company) |
22.35 |
21.04 |
24.39 |
| |
b. Non - Encumbered |
|
|
|
| |
- Number of shares |
5757233 |
3489289 |
4321233 |
| |
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) |
26.77 |
19.05 |
20.10 |
| |
- Percentage of shares (as a % of the total share capital of the company) |
8.17 |
4.96 |
6.14 |
|
| |
*EPS for the period (not annualised) |
| 1 |
The above unaudited financial results were approved by the Board of Directors at its meeting held on Friday, July 29, 2011 and have been subjected to limited review by the Statutory Auditors. |
| 2 |
The Company is operating in single segment (i.e) "Pharmaceuticals". |
| 3 |
Consolidated Results of the company |
Three months ended
30-Jun-11 |
Three months ended
30-Jun-10 |
Audited year ended
31-Mar-11 |
| |
Total Operating Income |
44,923.21 |
36,456.80 |
178,557.26 |
| |
EBIDTA (After Exceptional Item) |
8,894.23 |
8,243.11 |
42,182.11 |
| |
Profit After Tax |
1,692.25 |
2,353.25 |
15,618.72 |
| 4 |
Exceptional items represents exchange gain/(loss) on FCCBs. |
| 5 |
The Company received 16 complaints during the quarter ended June 30, 2011 from the shareholders and no complaints were pending at the close of the quarter. |
| 6 |
Previous year/period figures have been regrouped wherever necessary. |
| For and on behalf of the Board |
Place : Chennai
Date : July 29,2011 |
K. Raghavendra Rao
Chairman & Managing Director |
|